Convergence of dispersed regulatory mutations predicts driver genes in prostate cancer

Cancer sequencing predicts driver genes using recurrent protein-altering mutations, but detecting recurrence for non-coding mutations remains unsolved. Here, we present a convergence framework for recurrence analysis of non-coding mutations using three-dimensional co-localization of epigenomically-identified regions. We define the regulatory plexus of each gene as its cell-type-specific three-dimensional gene-regulatory neighborhood, inferred using Hi-C chromosomal interactions and chromatin state annotations. Using 16 matched tumor-normal prostate transcriptomes, we predict tumor-upregulated genes, and find enriched plexus mutations in distal regulatory regions normally repressed in prostate, suggesting out-of-context de-repression. Using 55 matched tumor-normal prostate genomes, we predict 15 driver genes by convergence of dispersed, low-frequency mutations into high-frequency dysregulation events along prostate-specific plexi, while controlling for mutational heterogeneity across regions, chromatin states, and patients. These putative drivers play roles in growth signaling, immune evasion, mitochondrial function, and vascularization, suggesting higher-order pathway-level convergence. We experimentally validate the PLCB4 plexus and its ability to affect the canonical PI3K cancer pathway.

[1]  C. Kahn,et al.  Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans. , 1993, Science.

[2]  Sukchan Lee,et al.  Translation of clock rhythmicity into neural firing in suprachiasmatic nucleus requires mGluR–PLCβ4 signaling , 2003, Nature Neuroscience.

[3]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[4]  K. Yu,et al.  Variants in circadian genes and prostate cancer risk: a population-based study in China , 2007, Prostate Cancer and Prostatic Diseases.

[5]  Clifford A. Meyer,et al.  FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific Transcription , 2008, Cell.

[6]  Eric T. Wang,et al.  An Abundance of Ubiquitously Expressed Genes Revealed by Tissue Transcriptome Sequence Data , 2009, PLoS Comput. Biol..

[7]  J. Stanford,et al.  Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. , 2009, Cancer research.

[8]  P. Polak,et al.  The evolution of transcription-associated biases of mutations across vertebrates , 2010, BMC Evolutionary Biology.

[9]  J. Stamatoyannopoulos,et al.  Human mutation rate associated with DNA replication timing , 2009, Nature Genetics.

[10]  Allen D. Delaney,et al.  LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer , 2010, BMC Medical Genomics.

[11]  G. Coetzee,et al.  8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC , 2010, Proceedings of the National Academy of Sciences.

[12]  S. Goodison,et al.  Targeting Sp1 transcription factors in prostate cancer therapy. , 2011, Medicinal chemistry (Shariqah (United Arab Emirates)).

[13]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[14]  M. Rubin,et al.  Oncogene-mediated alterations in chromatin conformation , 2012, Proceedings of the National Academy of Sciences.

[15]  A. Levine,et al.  Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer , 2012, Proceedings of the National Academy of Sciences.

[16]  Jason M. Johnson,et al.  A human homeotic transformation resulting from mutations in PLCB4 and GNAI3 causes auriculocondylar syndrome. , 2012, American journal of human genetics.

[17]  Swneke D. Bailey,et al.  Breast cancer risk-associated SNPs modulate the affinity of chromatin for FOXA1 and alter gene expression , 2012, Nature Genetics.

[18]  Data production leads,et al.  An integrated encyclopedia of DNA elements in the human genome , 2012 .

[19]  Jason H. Moore,et al.  Epigenomic Enhancer Profiling Defines a Signature of Colon Cancer , 2012, Science.

[20]  ENCODEConsortium,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[21]  Swneke D. Bailey,et al.  Integrative functional genomics identifies an enhancer looping to the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus , 2012, Genome research.

[22]  Andrey A. Shabalin,et al.  Matrix eQTL: ultra fast eQTL analysis via large matrix operations , 2011, Bioinform..

[23]  Manolis Kellis,et al.  ChromHMM: automating chromatin-state discovery and characterization , 2012, Nature Methods.

[24]  Gabor T. Marth,et al.  Integrative Annotation of Variants from 1092 Humans: Application to Cancer Genomics , 2013, Science.

[25]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[26]  Manolis Kellis,et al.  Interplay between chromatin state, regulator binding, and regulatory motifs in six human cell types , 2013, Genome research.

[27]  A. Lánczky,et al.  Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer , 2013, Proceedings of the National Academy of Sciences.

[28]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer-associated genes , 2013 .

[29]  X. Hua,et al.  DrGaP: a powerful tool for identifying driver genes and pathways in cancer sequencing studies. , 2013, American journal of human genetics.

[30]  S. De,et al.  DNA replication timing and higher-order nuclear organization determine single nucleotide substitution patterns in cancer genomes , 2013, Nature Communications.

[31]  Steven A. Roberts,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[32]  G. Prendergast,et al.  IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. , 2014, International immunology.

[33]  B. Brodin,et al.  Oncogenic Functions of the Cancer-Testis Antigen SSX on the Proliferation, Survival, and Signaling Pathways of Cancer Cells , 2014, PloS one.

[34]  J. Stamatoyannopoulos,et al.  Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair , 2013, Nature Biotechnology.

[35]  Jaana M. Hartikainen,et al.  Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation , 2014, Nature Communications.

[36]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[37]  Gary D Bader,et al.  Epigenomic alterations define lethal CIMP-positive ependymomas of infancy , 2014, Nature.

[38]  Kairong Cui,et al.  Aberrant TAL1 activation is mediated by an interchromosomal interaction in human T-cell acute lymphoblastic leukemia , 2014, Leukemia.

[39]  Zhaohui S. Qin,et al.  Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer , 2014, Nature.

[40]  M. Mann,et al.  The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer , 2014, Nucleic acids research.

[41]  C. Sheridan.  IDO inhibitors move center stage in immuno-oncology , 2015, Nature Biotechnology.

[42]  Manolis Kellis,et al.  Large-scale epigenome imputation improves data quality and disease variant enrichment , 2015, Nature Biotechnology.

[43]  Jun S. Liu,et al.  The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans , 2015, Science.

[44]  J. van Helden,et al.  Integrative analysis of public ChIP-seq experiments reveals a complex multi-cell regulatory landscape , 2014, Nucleic acids research.

[45]  Swneke D. Bailey,et al.  ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters , 2015, Nature Communications.

[46]  Michael Q. Zhang,et al.  Integrative analysis of 111 reference human epigenomes , 2015, Nature.

[47]  David C. Jones,et al.  Landscape of somatic mutations in 560 breast cancer whole genome sequences , 2016, Nature.

[48]  Stephen C. J. Parker,et al.  The genetic architecture of type 2 diabetes , 2016, Nature.

[49]  D. Schadendorf,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2022 .